^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The panel strongly recommends that TKI therapy at the prescribed daily dose should be continued as long as patients are receiving clinical benefit (response or stable disease).
